Powered by

Internationally-Recognized Immunologist Joins Batu Biologics' Quest to Destroy Solid Tumors

Oct 06, 2015 - Business Wire
Board and Executive Moves

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax(TM), announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board. In this capacity, Marincola will assist with the clinical development of ValloVax.

Marincola is the inaugural chief research officer of the Sidra Medical and Research Center (Sidra) based in Doha, Qatar, where he is tasked with building a world class, cutting-edge resear...